ROSSARI

Rossari Biotech Share Price

₹796.95 +3.5 (0.44%)

28 Dec, 2024 01:42

SIP TrendupStart SIP in ROSSARI

Start SIP

Performance

  • Low
  • ₹791
  • High
  • ₹800
  • 52 Week Low
  • ₹657
  • 52 Week High
  • ₹973
  • Open Price₹792
  • Previous Close₹793
  • Volume13,885

Investment Returns

  • Over 1 Month -3.62%
  • Over 3 Month -14.56%
  • Over 6 Month -0.43%
  • Over 1 Year + 0.13%
SIP Lightning

Smart Investing Starts Here Start SIP with Rossari Biotech for Steady Growth!

Invest Now

Rossari Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 31.8
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 4,412
  • P/B Ratio
  • 4.2
  • Average True Range
  • 23.78
  • EPS
  • 25.07
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -3.4
  • RSI
  • 44.82
  • MFI
  • 50.73

Rossari Biotech Financials

Rossari Biotech Technicals

EMA & SMA

Current Price
₹796.95
+ 3.5 (0.44%)
pointer
  • stock-down_img
  • Bullish Moving Average 2
  • stock-up_img
  • Bearish Moving Average 14
  • 20 Day
  • ₹808.92
  • 50 Day
  • ₹820.15
  • 100 Day
  • ₹825.84
  • 200 Day
  • ₹816.47

Resistance and Support

795.92 Pivot Speed
  • R3 810.23
  • R2 805.12
  • R1 801.03
  • S1 791.83
  • S2 786.72
  • S3 782.63

What's your outlook on Rossari Biotech?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Rossari Biotech is a leading specialty chemicals manufacturer in India, offering solutions across home and personal care, performance chemicals, and textile specialty chemicals. With three manufacturing plants, it serves clients in over 25 countries with sustainable chemical solutions.

Rossari Biotech has an operating revenue of Rs. 1,924.48 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 10% is healthy, ROE of 12% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 108 indicates it belongs to a poor industry group of Diversified Operations and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Rossari Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-19 Quarterly Results
2024-07-20 Quarterly Results
2024-04-29 Audited Results & Final Dividend
2024-01-20 Quarterly Results
2023-10-21 Quarterly Results

Rossari Biotech F&O

Rossari Biotech Shareholding Pattern

68.27%
13.18%
4.05%
3.74%
0%
9.56%
1.2%

About Rossari Biotech

  • NSE Symbol
  • ROSSARI
  • BSE Symbol
  • 543213
  • Managing Director
  • Mr. Sunil Chari
  • ISIN
  • INE02A801020

Similar Stocks to Rossari Biotech

Rossari Biotech FAQs

Rossari Biotech share price is ₹796 As on 28 December, 2024 | 01:28

The Market Cap of Rossari Biotech is ₹4411.6 Cr As on 28 December, 2024 | 01:28

The P/E ratio of Rossari Biotech is 31.8 As on 28 December, 2024 | 01:28

The PB ratio of Rossari Biotech is 4.2 As on 28 December, 2024 | 01:28

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23